Texas Capital Bank Wealth Management Services Inc Has $9.64 Million Position in Eli Lilly and Company (NYSE:LLY)

Texas Capital Bank Wealth Management Services Inc reduced its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,490 shares of the company's stock after selling 563 shares during the quarter. Eli Lilly and Company comprises approximately 1.0% of Texas Capital Bank Wealth Management Services Inc's investment portfolio, making the stock its 22nd largest position. Texas Capital Bank Wealth Management Services Inc's holdings in Eli Lilly and Company were worth $9,642,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Principal Financial Group Inc. increased its stake in Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock worth $1,070,698,000 after acquiring an additional 60,306 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its position in Eli Lilly and Company by 117.1% in the third quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock valued at $41,000 after buying an additional 24,879 shares during the last quarter. Wilson & Boucher Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 15.8% in the 3rd quarter. Wilson & Boucher Capital Management LLC now owns 740 shares of the company's stock valued at $656,000 after buying an additional 101 shares during the period. Sunbelt Securities Inc. lifted its stake in Eli Lilly and Company by 9.6% during the 3rd quarter. Sunbelt Securities Inc. now owns 5,453 shares of the company's stock worth $4,831,000 after acquiring an additional 477 shares in the last quarter. Finally, Fortem Financial Group LLC boosted its holdings in Eli Lilly and Company by 23.7% during the 3rd quarter. Fortem Financial Group LLC now owns 2,038 shares of the company's stock valued at $1,806,000 after acquiring an additional 390 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on LLY. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Guggenheim cut their target price on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a report on Monday. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research note on Friday, January 17th. Finally, Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a report on Thursday, January 16th. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,012.00.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $13.83 during mid-day trading on Monday, hitting $746.24. 1,638,335 shares of the company's stock traded hands, compared to its average volume of 3,379,630. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm's 50 day simple moving average is $837.05 and its 200 day simple moving average is $822.87. The company has a market cap of $707.56 billion, a PE ratio of 63.73, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.